Adalimumab Dosing Regimen
The recommended adalimumab dosing regimen varies by indication, with FDA-approved protocols specifying higher induction doses for inflammatory bowel disease (160 mg at week 0,80 mg at week 2, then 40 mg every other week starting week 4) compared to other conditions, while hidradenitis suppurativa and psoriasis follow the same induction pattern but hidradenitis suppurativa requires weekly maintenance dosing (40 mg weekly starting week 4). 1
Crohn's Disease
For Crohn's disease, the FDA-approved induction regimen is:
- Week 0: 160 mg subcutaneously
- Week 2: 80 mg subcutaneously
- Week 4 onwards: 40 mg every other week for maintenance 1
This loading dose strategy is critical for achieving adequate drug levels during active disease. Allow up to 8 weeks of maintenance therapy before determining non-response 2. Approximately 40% of week 12 non-responders may achieve response by week 36 with continued treatment 3.
Dose escalation consideration: If patients experience loss of response during maintenance, escalation to 40 mg weekly may be beneficial 2. However, evidence suggests that patients failing 40 mg every other week who require further escalation to 80 mg weekly show limited benefit, with only 33% achieving clinical remission 4.
Ulcerative Colitis
The dosing regimen mirrors Crohn's disease:
- Induction: 160 mg at week 0,80 mg at week 2
- Maintenance: 40 mg every other week starting week 4 1
The same principle applies: higher induction doses are used during active disease to rapidly achieve therapeutic drug levels, followed by standard maintenance dosing.
Hidradenitis Suppurativa
Hidradenitis suppurativa requires weekly maintenance dosing unlike other indications:
- Week 0: 160 mg subcutaneously
- Week 2: 80 mg subcutaneously
- Week 4 onwards: 40 mg weekly (not every other week) 3, 1
This weekly dosing is FDA-approved and was established in the PIONEER trials, where weekly dosing achieved 42-59% HiSCR response at 12 weeks versus 26-28% with placebo 3. Critical caveat: Almost half of week 12 responders lost response by week 36 despite continued weekly dosing, while conversely, nearly 40% of week 12 non-responders achieved response by week 36 with continued treatment 3. This underscores the need for patience before declaring treatment failure.
Plaque Psoriasis
For plaque psoriasis, the regimen is:
- Week 0: 80 mg subcutaneously
- Week 1: 40 mg subcutaneously
- Week 2 onwards: 40 mg every other week 1
Note the different induction pattern compared to IBD—psoriasis uses a lower initial loading dose (80 mg vs 160 mg) and begins maintenance dosing earlier.
Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
These inflammatory arthritis conditions use no loading dose:
- Standard dosing: 40 mg every other week from initiation 1
This reflects that these conditions typically don't require the aggressive induction approach needed for active IBD 5.
Key Clinical Considerations
Monitoring timeline: Evaluate treatment response at 12 weeks for hidradenitis suppurativa and up to 8 weeks for Crohn's disease before determining non-response 3, 2. Do not prematurely discontinue therapy.
Recurrent symptoms during maintenance: Fully evaluate new or recurrent symptoms to distinguish true inflammatory disease activity from alternative causes such as intercurrent infection, bile acid diarrhea, or irritable bowel syndrome before escalating doses 2.
Proactive therapeutic drug monitoring: Current guidelines provide a weak recommendation against routine proactive TDM for adalimumab during maintenance therapy, primarily due to very low certainty evidence and the burden of additional clinic visits for a self-administered subcutaneous medication 5. Reactive TDM (measuring levels only when symptoms worsen) remains more appropriate for adalimumab.
Safety profile: Weekly and every-other-week dosing show comparable safety profiles across all indications, with no new safety signals identified with more frequent dosing 6.